Amphithéâtre Marguerite de Navarre, Site Marcelin Berthelot
Open to all
-

Abstract

Type 2diabetes and obesity are global epidemics, associated with high rates of morbidity and mortality. These diseases significantly reduce patients' life expectancy and represent a major economic burden for public health systems. Often stigmatized, they are frequently perceived as the result of patients' unwillingness to adopt a healthy diet or engage in regular physical activity. However, we will see that these pathologies have a predominantly genetic component. We will highlight how genetic studies not only help to improve patient care in the context of personalized medicine, but also contribute to the discovery of promising new therapeutic targets.

Speaker(s)

Amélie Bonnefond

Director of Research at Inserm CNRS/Inserm UMR8199/1283, Université de Lille, Institut Pasteur de Lille, CHU de Lille